Summary: Infection with the SARS-CoV-2 virus causes the COVID-19 coronavirus disease. Although this is an infectious disease involving mainly the lungs, many organs – including the liver – are also affected. The disease impairs liver function and has a detrimental effect on the course of many chronic liver diseases. Since the COVID-19 epidemic began, a great many papers on the disease and its liver manifestations have been published. Increased aminotransferase activity has been described especially often in serious forms of COVID-19. SARS-CoV-2 infection has a direct negative impact on chronic liver disease, while antiviral pharmacotherapy and other drugs taken for COVID-19 have undesirable effects on the liver. Patients who have recovered from the infection are sure to be left with negative effects on their liver, perhaps similarly to recovery from lung disease. The course of the acute stage of SARS-CoV-2 infection depends on the intensity of response of different cells and organs, including the liver, but the clinical picture of COVID-19 outcomes is not yet known. Further observation of how having the infection affects convalescence is essential; without major forward-looking research it is difficult to obtain information solely from case histories or studies on relatively small groups. The aim of the paper is to show how biochemical liver indicators behave in COVID-19 patients, and also to draw attention to the course of selected chronic liver diseases during the pandemic. This could be important for further care provided to patients who have had COVID-19.